May 2025, Vol 15, No 5

Exposing our organizations to the importance of revenue cycle management (RCM) arms them with knowledge critical to identifying and overcoming obstacles throughout the RCM maze. Read More ›

Even with approved targeted therapies for gastric cancer, many patients are still not receiving targeted therapy. Read More ›

Officials with the FDA have granted traditional approval to pembrolizumab (Keytruda; Merck) with trastuzumab- (Herceptin; Genentech), fluoropyrimidine-, and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express programmed death-ligand 1 (PD-L1) with a combined positive score (CPS) ≥1. Read More ›

Cabozantinib (Cabometyx; Exelixis, Inc) has been approved by the FDA for use in patients aged >12 years who had previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET). Read More ›

On March 28, 2025, the FDA expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto; Novartis) to include adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy and who are considered appropriate to delay taxane-based chemotherapy. Read More ›

FDA officials recently approved durvalumab (Imfinzi; AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle-invasive bladder cancer. Read More ›

Officials with the FDA recently issued a communication in an attempt to increase awareness of recent updates to the product labeling of capecitabine and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. Read More ›

Despite advances in first-line treatment, long-term prognosis for advanced non–small cell lung cancer (NSCLC) remains poor. Read More ›

Officials with GenFleet Therapeutics announced phase 2 data from the KROCUS study, fulzerasib (GFH925, KRAS G12C inhibitor) in combination with cetuximab for first-line non–small cell lung cancer (NSCLC) treatment in a late-breaking abstract at the mini oral presentation of the 2025 European Lung Cancer Congress. Read More ›

Updated results from the phase 2 KRYSTAL-7 study continue to highlight the potential of first-line adagrasib (Krazati; Bristol Myers Squibb) combined with pembrolizumab (Keytruda; Merck) in patients with advanced or metastatic KRAS G12C–mutated non–small cell lung cancer (NSCLC) and programmed death-ligand 1 (PD-L1) tumor proportion score of ≥50%. Read More ›

Study results presented at the European Lung Cancer Congress 2025 demonstrate the role of osimertinib (Tagrisso; AstraZeneca), as monotherapy across stages and settings of EGFR-mutated non–small cell lung cancer. Read More ›

The evolution of precision medicine has transformed oncology, offering targeted treatment strategies tailored to individual patients. However, for many healthcare practitioners, effectively applying precision medicine in clinical practice remains a significant challenge. Read More ›